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A B S T R A C T
A 24-year-old woman was admitted to our hospital with the diagnosis of pulmonary thromboembolism
(PTE) and left common iliac vein thrombosis. She had used low-dose contraceptive pill for
dysmenorrhea. Otherwise, her laboratory data did not show any other thrombotic risk factors.
Thrombus in the common iliac vein usually requires a permanent inferior vena cava (IVC) ﬁlter.
However, the use of long-term warfarin should have been avoided for her potential future pregnancy. A
retrievable IVC ﬁlter was placed and catheter directed thrombolysis was performed for her deep vein
thrombosis (DVT). Local injection of monteplase from a pulse spray catheter was performed for 4 days.
After the catheter-based treatment, the thrombus resolved and the IVC ﬁlter was successfully removed
on day 19. The patient was discharged on day 21. Warfarin therapy was discontinued 6 months after
discharge.
<Learning objective: Urokinase is recommended in the guideline of the Japanese Circulation Society.
But the dose is much less than those stated in guidelines overseas. Several studies have shown that
tissue-plasminogen activator (t-PA) might be more effective than urokinase. We report a case in which
local injection of monteplase, a type of long acting t-PA, for DVT was effective in treating PTE and DVT.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Several reports have shown the effectiveness of catheter
intervention for severe deep vein thrombosis (DVT), catheter
directed thrombolysis (CDT) [1,2].
In most reports of CDT, the researchers used local infusion of
urokinase. The guideline of the Japanese Circulation Society
recommends urokinase 240,000 U/day [4].
However, the dose is much smaller than recommendations of
the US guideline [3]. Moreover, it is also smaller than that of
pulmonary thromboembolism (PTE) in Japan [4].* Corresponding author at: Showa University Northern Yokohama Hospital,
Division of Cardiology and Cardiac Catheterization Laboratories, 35-1,
Chigasaki-Chuo, Tsuzuki, Yokohama 224-8503, Japan. Tel.: +81 045 949 7000;
fax: +81 045 949 7117.
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsIn the treatment of PTE, tissue-plasminogen activator (t-PA) is
potentially more effective and safer than urokinase. We now report
a case in which monteplase, a type of long acting t-PA, local
injection for DVT was effective.
Case report
A 24-year-old woman visited our hospital complaining of left
femoral pain and left leg pitting edema from 2 weeks previously.
Contrast computed tomography (CT) showed PTE and thrombus
from left common iliac vein to femoral vein (Fig. 1a–d). She had
used low-dose contraceptive pill for dysmenorrhea. Laboratory
data did not show any other thrombotic tendency. Ultrasound
cardiography showed mild tricuspid regurgitation and tricuspid
gradient was 30 mmHg.
The severity classiﬁcation of PTE was submassive class. reserved.
Fig. 1.
Contrast computed tomography on admission showed pulmonary
thromboembolism and thrombus from left common iliac vein to
femoral vein.
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was 47.6 kg. Her body temperature was 37.3 8C, blood pressure
128/70 mmHg, heart rate 78 min–1 (regular), and SpO2 100% (O2
3 L). Her liver was not palpable and she had leg and pedal edema
mainly on the left side. The initial blood examination was as
follows: white blood cell count 10,900 mL1, hemoglobin 14.0 g/
dL, platelet count 19.9  104 mL1, d-dimer 11.4 mg/dL, activated
partial thromboplastin time 28.5 s, prothrombin time and inter-
national normalized ratio 0.98, ﬁbrinogen 388 mg/dL, antithrom-
bin III 95%, total protein 6.9 g/dL, albumin 3.9 g/dL, blood urea
nitrogen 9.0 mg/dL, creatinine 0.73 mg/dL, aspartate aminotrans-
ferase 16 IU/L, alanine aminotransferase 12 IU/L, creatine kinase
41 IU/L, troponin T negative, lactate dehydrogenase 218 IU/L, Na
138 mEq/L, K 4.6 mEq/L, Cl 106 mEq/L, antinuclear antibody
negative, ds-DNA antibody 1.8 IU/mL, protein C 81%, protein S
74.8%, soluble interleukin-2 receptor 379 U/mL, antineutrophil
cytoplasmic antibody (C-ANCA and P-ANCA) negative, antic-
ardilolipin b2-glycoproteinl complex antibody negative, rheuma-
toid factor 2 U/mL, homocysteine 5.6 mmol/mL, and C-reactive
protein 1.31 mg/dL. The admission electrocardiogram showed
normal sinus rhythm without right ventricular strain. A chest X-
ray showed a normal cardiothoracic ratio (49.4%) with clear lung
ﬁelds.
After diagnosis of PTE and DVT, an inferior vena cava (IVC)
ﬁlter (Gunther Tulip1, Cook Medical, Bloomington, IN, USA) was
placed followed by intravenous injection of monteplase
27,500 U/kg. Six hours after the injection, we started heparin
(15,000 U per daily) and warfarin (5 mg/day). The low-dose
contraceptive pill was discontinued. On day 2, ﬁbrinogen/ﬁbrin
degradation product and d-dimer were signiﬁcantly increased
(215 mg/mL and 60.3 mg/mL, respectively). However, her left leg
edema did not show signiﬁcant improvement. Therefore, we
decided to perform catheter intervention. A 7 Fr guiding sheath
(Ansel1, Cook Medical) was inserted from the left popliteal vein.
The venography showed left iliac vein and common femoral vein
almost occluded by thrombus (Fig. 2a and b). We repeatedly
performed thrombus aspiration from the guiding sheath and
attempted to crush thrombus of common iliac vein by rotating a
pig tail catheter and a balloon (Synergy1 8.0 mm  40 mm,
Boston Scientiﬁc, Natick, MA, USA). After blood ﬂow from the
left popliteal vein to IVC was conﬁrmed by venography, a pulse
spray catheter (PULSE SPRAY1, TORAY Medical, Chiba, Japan)
was placed in the left common iliac vein. We injected
monteplase 27,500 U/kg through the catheter at the end of
the procedure. From day 3 to day 5, monteplase was injected
through the catheter at a dose of 4500 U/kg three times a day.
On day 5, we performed venography and observed small
thrombus was at the femoral and common iliac vein. However,
most of the thrombus was resolved and blood ﬂow was greatly
improved (Fig. 2c and d). Pulse spray catheter was retrieved
after venography. On day 14, contrast CT showed that iliac vein
thrombus was completely resolved (Fig. 3a–d). The IVC ﬁlter
was retrieved on day 19 and the patient was discharged on day
21. Warfarin was prescribed for 6 months. Six months after
discharge, follow-up contrast CT showed no recurrence of
thrombosis. She had no post-thrombotic syndrome. The patient
is subsequently taking aspirin 100 mg daily [5].
Discussion
DVT is a common disease, and most of the DVT patients are
treated with anticoagulant therapy such as heparin and warfarin.
However, anticoagulant therapy is not effective for some cases. For
example, when thrombus burden is massive or DVT is due to iliac
compression syndrome, CDT might be indicated. The guideline of
Fig. 2.
Venography before and after catheter directed thrombolysis (CDT), local injection of tissue-plasminogen activator. (a and b) The venography before CDT with left
iliac vein and common femoral vein almost occluded by thrombus. (c and d) The venography on day 5, when we observed that a small thrombus was at the
femoral and common iliac vein. However, most of the thrombus was resolved and blood ﬂow was greatly improved.
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[4].
The patient was young, and desired to bear children. Therefore,
we needed to avoid the long-term use of warfarin. IVC ﬁlter
placement is also problematic. Deformation of IVC ﬁlter or
perforation caused by compression from pregnant uterus has
been reported [6]. On the other hand, the successful retrieval rate
of IVC ﬁlters is over 90% up to 3 months after the placement [7].
Over time, tissue grows slowly and covers the IVC ﬁlter. That is a
reason why the successful retrieval rate decreases to 60% at 6
months after IVC ﬁlter placement [7,8].
Her thrombus was located in the left common iliac vein and
proximal femoral vein. Standard therapy using only anticoagula-
tion might not resolve thrombus within 3 months. Since we needed
to resolve the thrombus and retrieve the IVC ﬁlter in a few months,
we chose to perform local thrombolytic therapy and CDT. Alteplase
was injected at about half the dose used for PTE in a previous study.
Thus we injected monteplase at about half the dose used for PTE in
this case [1].
Alteplase was the ﬁrst recombinant t-PA. It had a half-life
of only 4 min. Monteplase is a modiﬁed t-PA. The half-life time
of monteplase is more than 20 min, which is ﬁve times of that ofalteplase [9]. Urokinase is the only agent approved by the
Japanese Ministry of Health, Labour and Welfare for thrombol-
ysis in DVT. However, the dose of urokinase recommended in
the guideline of the Japanese Circulation Society is not adequate.
The dose of urokinase is 120,000–180,000 U/h in the USA (in this
patient, 2,880,000–4,320,000 U/day); however, the dose is lower
in Japan (240,000 U/day). Some reports showed that local
injection of t-PA or urokinase was more effective compared to
heparin therapy [1]. Goldhaber et al. reported that continuous
intravenous infusion of t-PA plus heparin resolved more
thrombus than heparin alone for proximal DVT and bleeding
complications were similar [2]. Ouriel et al. published a report
comparing streptokinase, urokinase, and t-PA in an in vitro
model of vein thrombolysis. It has shown t-PA associated with
the most rapid rate of thrombolysis. Fibrinogen degradation was
higher with t-PA than with urokinase. Cost efﬁciency was
similar in urokinase and t-PA perfusions [10].
We experienced a proximal DVT case in which local injection of
monteplase was effective. Although urokinase is the only agent
approved for local injection in DVT patients in Japan, monteplase
might be an alternative treatment option, especially in cases that
need rapid resolution of thrombus.
Fig. 3.
Contrast computed tomography at day 14 showed that iliac vein
thrombus was completely resolved.
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